ArticleFundamental & clinical pharmacology2026
Residual Effects of Acute and Subchronic Zolpidem Treatments on Attentional Processes in Aged Female Rats.
Article in Fundamental & clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Differential Dose-Response Behavioural Profiles of Diazepam, Zolpidem and Indiplon in a Two-Trial Y-Maze Paradigm in Rats.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Residual Effects of Acute and Subchronic Zolpidem Treatments on Attentional Processes in Aged Female Rats.Fundamental & clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
rationalZolpidem, a hypnotic Z-drug commonly prescribed to promote sleep, is predominantly used over the age of 50. In this elderly population, adverse behavioral disturbances, impaired driving performance, and an increased risk of falls have been frequently reported. These concerns have raised questions about the residual adverse effects of zolpidem in older adults, particularly on cognitive processes such as executive and attentional functions.
objectivesThis study aimed to investigate the residual effects of zolpidem on attentional performance following either acute or subchronic administration in aged rats.
methodsA zolpidem dose of 3 mg/kg and a 3-h postadministration time point were selected based on pharmacokinetic data from the literature and a dose-response analysis of its locomotor effects in the open-field test. Attentional performance was then assessed in aged female rats treated with either saline or zolpidem (acutely or for 7 days), using the 5-choice continuous performance task (5C-CPT).
resultsAcute zolpidem administration significantly reduced the percentage of correct responses, increased correct response latency, and showed a trend toward more omissions, indicative of impaired attentional performance and psychomotor slowing. These effects were not further observed after subchronic treatment, suggesting a potential tolerance over time.
conclusionOur findings highlight a critical period of vulnerability following the initiation of zolpidem treatment, during which residual cognitive impairments may emerge. Such effects may compromise complex tasks requiring sustained attention and processing speed, such as driving, especially in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.